Inactive Instrument

Analyst Reco. IPI Legacy Liquidation Co

Equities

IMPL

US45258K1097

Delayed OTC Markets Other stock markets 19:08:57 05/04/2024 BST			5-day change	1st Jan Change
0.015 ^USD	-.--%		-.--%	-87.85%

04-12	North American Morning Briefing : Big Banks Kick -2-	DJ
04-05	North American Morning Briefing : Investors on -2-	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Investors on -2-	04-05	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	11-20	DJ
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	08/09/23	MT
JonesTrading Downgrades Impel Pharmaceuticals to Hold From Buy	18/08/23	MT
Wedbush Adjusts Impel Pharmaceuticals' Price Target to $2 From $4, Maintains Neutral Rating	24/03/23	MT
Wedbush Trims Impel Pharmaceuticals' Price Target to $4 From $5 Following Announcement of Corporate Restructuring, Keeps Neutral Rating	23/02/23	MT
Wedbush Downgrades Impel Pharmaceuticals to Neutral From Outperform, Lowers Trudhesa Revenue Estimates as Commercial Traction Remains Elusive; Cuts PT to $5 From $24	15/11/22	MT
Cowen & Co Adjusts Impel Pharmaceuticals Price Target to $40 From $55, Maintains Outperform Rating	14/11/22	MT
Wedbush Cuts Price Target on Impel Pharmaceuticals to $24 From $28, Keeps Outperform Rating	13/10/22	MT
JonesTrading Starts Impel Pharmaceuticals at Buy With $26 Price Target	25/08/22	MT
Wedbush Lowers Price Target for Impel NeuroPharma to $28 From $31, Maintains Outperform Rating	15/08/22	MT
Wedbush Trims Impel NeuroPharma's Price Target to $31 From $32, Keeps Outperform Rating	28/04/22	MT
Guggenheim Adjusts Impel NeuroPharma Price Target to $35 From $50, Maintains Buy Rating	25/03/22	MT
Wedbush Lowers Impel NeuroPharma's Price Target to $32 From $40; Outperform Rating Kept	25/01/22	MT
Wedbush Lifts Price Target on Impel NeuroPharma to $40 From $39; Outperform Rating Kept	16/11/21	MT
IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $39 From $37, Maintains Outperform Rating	15/09/21	MT
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Chipotle Mexican Grill, Netflix, Vodafone...	08/09/21
IMPEL NEUROPHARMA : Guggenheim Adjusts Impel NeuroPharma PT to $50 From $32, Maintains Buy Rating	07/09/21	MT
IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $37 From $31, Maintains Outperform Rating	07/09/21	MT
IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $31 From $25 Ahead of Investor Meeting on Trudhesa Launch Plans, Maintains Outperform Rating	03/09/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. IPI Legacy Liquidation Co

Equities

IMPL

US45258K1097

Analyst Reco.

Filters